The earnings call reflects a strong performance by Pharming with significant revenue growth and product expansion. The company has successfully turned around its operating profit and upgraded its revenue guidance. However, challenges such as acquisition-related expenses and potential market competition were noted.

Company Guidance

During the Q2 2025 earnings call, Pharming provided updated guidance based on strong financial performance, with total revenues increasing by 26% compared to the same period last year, driven by a 28% year-on-year growth in RUCONEST and significant patient uptake for Joenja. The operating profit reached $12.9 million, excluding $2 million in nonrecurring expenses related to the Abliva acquisition. The company upgraded its full-year 2025 revenue guidance to between $335 million and $350 million, reflecting a 13% to 18% growth. Operating expenses are expected to be between $304 million and $308 million, slightly above previous guidance, partially due to currency exchange impacts. Pharming also emphasized the continued expansion of Joenja in the U.K. and upcoming launches in Japan, the EU, and Canada, alongside a strong pipeline with potential blockbuster assets.

Strong Revenue Growth

Pharming delivered a strong quarter with total revenues growing by 26% in Q2 2025 compared to the same quarter last year. Operating profit reached $12.9 million, a significant turnaround from a loss in the previous year.

RUCONEST and Joenja Performance

RUCONEST revenues grew by 28% year-on-year, reaching $80.4 million. Joenja also saw strong performance with a 15% quarter-on-quarter revenue growth, achieving $12.8 million in net revenue.

Pipeline and Product Expansion

Pharming has expanded its pipeline with the acquisition of KL1333 and ongoing development of Joenja for new indications. Joenja has been successfully launched in the UK, and regulatory applications for label expansion have been filed in Japan and with the FDA.

Upgraded Revenue Guidance

Pharming raised its 2025 total revenue guidance to between $335 million and $350 million, up from the prior guidance of $325 million to $340 million.

Pharming Group (PHGUF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PHGUF Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	0.00 / -	-0.002	―	―	―
Jul 31, 2025	2025 (Q2)	-0.01 / <0.01	-0.002	400.00% (<+0.01)
May 08, 2025	2025 (Q1)	>-0.01 / -0.02	-0.019	-15.79% (>-0.01)
Mar 13, 2025	2024 (Q4)	<0.01 / <0.01	-0.004	225.00% (<+0.01)
Oct 24, 2024	2024 (Q3)	0.00 / >-0.01	0	―
Aug 01, 2024	2024 (Q2)	0.00 / >-0.01	0.001	-300.00% (>-0.01)
May 08, 2024	2024 (Q1)	<0.01 / -0.02	-0.017	-11.76% (>-0.01)
Mar 14, 2024	2023 (Q4)	0.00 / >-0.01	-0.02	80.00% (+0.02)
Oct 26, 2023	2023 (Q3)	-0.01 / 0.00	0.04	―
Aug 03, 2023	2023 (Q2)	-0.01 / <0.01	0.022	-95.45% (-0.02)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PHGUF Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$0.98	$0.98	0.00%
May 08, 2025	$0.88	$0.88	0.00%
Mar 13, 2025	$0.79	$0.90	+13.92%
Oct 24, 2024	$0.91	$0.81	-10.99%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Pharming Group (PHGUF) report earnings?

Pharming Group (PHGUF) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).

What is Pharming Group (PHGUF) earnings time?

Pharming Group (PHGUF) earnings time is at Nov 06, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PHGUF EPS forecast?

PHGUF EPS forecast for the fiscal quarter 2025 (Q3) is 0.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing